Literature DB >> 25032121

The protective role of molsidomine on the Cisplatin-induced ototoxicity.

Yuksel Toplu1, Hakan Parlakpinar2, Emrah Sapmaz3, Erkan Karatas1, Alaattin Polat4, Ahmet Kizilay1.   

Abstract

This experimental study was designed to investigate the protective effects of molsidomine (MOL) on against cisplatin-induced ototoxicity (CIO). To examine this effect, distortion product otoacoustic emissions (DPOAEs) measurements and serum levels of oxidative and antioxidant status [including malondialdehyde (MDA), superoxide dismutase (SOD), catalase (CAT), glutathione (GSH), glutathione peroxidase (GPX), total oxidant status (TOS), total antioxidant status (TAS), and oxidative stress index (OSI)] were evaluated. Thirty-two female wistar albino rats were divided into four groups including; control (Group K), cisplatin (Group C), cisplatin plus MOL group (Group CM), and MOL group (Group M). DPOAEs measurements between 0.9961 and 8.0003 Hz as DP-gram and input/output (I/O) functions were performed in the same (left) ear of all rats on days 0, 1st, 5th and 12th. Prior to death, the last DPOAEs measurements and blood samples were taken. In the C group, statistically significant DPOAE amplitude reductions were detected at 2.5195, 3.1758, 3.9961, 5.0391, 6.3516 and 8.0039 Hz frequencies (p < 0.05) between 0th and 1st, 0th and 5th and 0th and 12th days' measurements (p < 0.05). Serum level of MDA, TAC and OSI levels were significantly higher in the C group versus K group (p < 0.05). In the CM group, there were no significant differences at all frequencies between 0th and other days' measurements (p > 0.05) and the serum levels of all biochemical parameters were shifted toward normal values, similar to the K group (p < 0.05). No significant differences were detected in the either M or K group's measurements. According to these results, cisplatin-related ototoxicity has been significantly prevented by MOL.

Entities:  

Keywords:  Cisplatin; Molsidomine; Otoacoustic emissions; Ototoxicity; Oxidative status

Year:  2014        PMID: 25032121      PMCID: PMC4071436          DOI: 10.1007/s12070-014-0718-2

Source DB:  PubMed          Journal:  Indian J Otolaryngol Head Neck Surg        ISSN: 2231-3796


  28 in total

1.  A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation.

Authors:  Ozcan Erel
Journal:  Clin Biochem       Date:  2004-04       Impact factor: 3.281

2.  Decreased total antioxidant capacity and increased oxidative stress in passive smoker infants and their mothers.

Authors:  Ali Aycicek; Ozcan Erel; Abdurrahim Kocyigit
Journal:  Pediatr Int       Date:  2005-12       Impact factor: 1.524

Review 3.  Ototoxicity: therapeutic opportunities.

Authors:  Leonard P Rybak; Craig A Whitworth
Journal:  Drug Discov Today       Date:  2005-10-01       Impact factor: 7.851

4.  A simple method for clinical assay of superoxide dismutase.

Authors:  Y Sun; L W Oberley; Y Li
Journal:  Clin Chem       Date:  1988-03       Impact factor: 8.327

5.  Effects of molsidomine against doxorubicin-induced cardiotoxicity in rats.

Authors:  O M Disli; E Sarihan; M C Colak; N Vardi; A Polat; J Yagmur; B Tamtekin; H Parlakpinar
Journal:  Eur Surg Res       Date:  2013-10-23       Impact factor: 1.745

6.  Cyclic GMP as the mediator of molsidomine-induced vasodilatation.

Authors:  W R Kukovetz; S Holzmann
Journal:  Eur J Pharmacol       Date:  1986-03-11       Impact factor: 4.432

7.  Mechanism of cisplatin ototoxicity: antioxidant system.

Authors:  R Ravi; S M Somani; L P Rybak
Journal:  Pharmacol Toxicol       Date:  1995-06

Review 8.  Comparative adverse effect profiles of platinum drugs.

Authors:  M J McKeage
Journal:  Drug Saf       Date:  1995-10       Impact factor: 5.606

Review 9.  Cisplatin ototoxicity and protection: clinical and experimental studies.

Authors:  Leonard P Rybak; Debashree Mukherjea; Sarvesh Jajoo; Vickram Ramkumar
Journal:  Tohoku J Exp Med       Date:  2009-11       Impact factor: 1.848

10.  Intrarenal administration of molsidomine, a molecule releasing nitric oxide, reduces renal ischemia-reperfusion injury in rats.

Authors:  Ana Rodriguez-Peña; Francisco J Garcia-Criado; Nelida Eleno; Miguel Arevalo; Jose M Lopez-Novoa
Journal:  Am J Transplant       Date:  2004-10       Impact factor: 8.086

View more
  2 in total

1.  Protective role of misoprostol against cisplatin-induced ototoxicity.

Authors:  Murat Doğan; Halil Polat; Mehmet Yaşar; Altan Kaya; Ali Bayram; Fatma Şenel; İbrahim Özcan
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-04-06       Impact factor: 2.503

2.  Molsidomine ameliorates diabetic peripheral neuropathy complications in Wistar rats.

Authors:  Pranav Nayak B; Nathani Minaz; Khadar Pasha
Journal:  Animal Model Exp Med       Date:  2021-03-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.